Clinical response in patients with ovarian cancer treated with metronomic chemotherapy

Ovarian cancer (OC) is the leading cause of death from gynaecological cancer. It is extremely hard to diagnose in the early stages and around 70% of patients present with advanced disease. Metronomic chemotherapy (MCT) is described as the chronic administration of, generally low, equally spaced, dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Perroud, Herman Andrés, Scharovsky, O Graciela, Rozados, Viviana Rosa, Alasino, Carlos María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2017
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336390/
https://www.ncbi.nlm.nih.gov/pubmed/28275392
http://dx.doi.org/10.3332/ecancer.2017.723
Descripción
Sumario:Ovarian cancer (OC) is the leading cause of death from gynaecological cancer. It is extremely hard to diagnose in the early stages and around 70% of patients present with advanced disease. Metronomic chemotherapy (MCT) is described as the chronic administration of, generally low, equally spaced, doses of chemotherapeutic drugs with therapeutic efficacy and low toxicity. This is an effective and low-cost way to treat several types of tumours, including ovarian cancer. Here, we present six cases of advanced ovarian cancer treated with MCT with low doses of cyclophosphamide, which showed clinical response and stable disease.

Ejemplares similares